Horizon Therapeutics (HPTX) and The Competition Head to Head Contrast

Horizon Therapeutics (NASDAQ: HPTX) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its peers? We will compare Horizon Therapeutics to similar companies based on the strength of its institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Therapeutics 0 0 0 0 N/A
Horizon Therapeutics Competitors 143 805 1780 60 2.63

As a group, “Biopharmaceuticals” companies have a potential upside of 10.10%. Given Horizon Therapeutics’ peers higher possible upside, analysts clearly believe Horizon Therapeutics has less favorable growth aspects than its peers.

Profitability

This table compares Horizon Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horizon Therapeutics 23.13% 21.30% 15.42%
Horizon Therapeutics Competitors -13,897.70% -98.18% -24.83%

Insider & Institutional Ownership

43.1% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Horizon Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Horizon Therapeutics N/A N/A -1,533.00
Horizon Therapeutics Competitors $564.12 million $96.17 million 64.09

Horizon Therapeutics’ peers have higher revenue and earnings than Horizon Therapeutics. Horizon Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Horizon Therapeutics peers beat Horizon Therapeutics on 5 of the 8 factors compared.

About Horizon Therapeutics

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply